// App-Quantinova.ai

PP19-4 : Early Weight Loss Responders to Liraglutide 3.0 Mg Achieved Greater Weight Loss and Regression to Normoglycemia, and Reduced Development of T2D, at 3 Years Versus Early Non-Responders in the Scale Obesity and Prediabetes Trial

Researchers

Presenter

  • Frank Lyons Greenway

Principal Investigators

  • David C.W. Lau

  • Patrick M. -Neil

  • Sten Madsbad

  • Soren Kruse Lilleore

  • Trine Vang Skjoth

  • John Wilding

Medical Centers

  • University Hospital Aintree, Liverpool, United Kingdom

  • Pennington Biomedical Research Center, Baton Rouge, LA.

  • Medcl Univ of South Carolina, Charleston, SC

  • Scripps Clinic, La Jolla, CA.

  • University of Calgary, Cumming School of Medicine, Calgary, AB, Canada

  • Hvidovre Hospital, Hvidovre, Denmark

Locations

  • United States

  • Canada

  • United Kingdom

  • Denmark

Companies

  • Novo Nordisk A/S

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Dyslipidemia

  • Hypertension

  • Prediabetes

  • Obesity

Biomarkers

  • Hemoglobin A1c

  • Sex hormone binding globulin

  • Body mass index

Drug/Treatment

  • Liraglutide

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved